Dr. Oxnard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave
Moakley 3RD Foor
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2008
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2005
Certifications & Licensure
MA State Medical License 2007 - 2025
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
NY State Medical License 2008 - 2011- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Afatinib With CT and RT for EGFR-Mutant NSCLC Start of enrollment: 2012 Apr 01
- INHERIT EGFR - Studying Germline EGFR Mutations Start of enrollment: 2012 Dec 28
- Sunitinib in Never-Smokers With Lung Adenocarcinoma Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsPan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase...Jay A Moore, Kuei-Ting Chen, Russell Madison, Justin Y Newberg, Zoe Fleischmann
JCO Precision Oncology. 2023-09-01 - 331 citationsInstitutional implementation of clinical tumor profiling on an unselected cancer populationLynette M. Sholl, Khanh T. Do, Priyanka Shivdasani, Ethan Cerami, Adrian M. Dubuc
JCI Insight. 2016-11-17 - 269 citationsTATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerGeoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu, Sang We Kim, Hideo Saka
Annals of Oncology. 2020-04-01
Journal Articles
- Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small Cell Lung CancerG R Oxnard, G M Blumenthal, P G Kluetz, R Pazdur, Annals of Oncology
- Institutional Implementation of Clinical Tumor Profiling on an Unselected Cancer PopulationKhanh Do, Lauren L Ritterhouse, William C Hahn, Geoffrey I Shapiro, Barrett J Rollins, Neal I Lindeman, Alanna Church, Geoffrey R Oxnard, Bruce E Johnson, Frank C Kuo,..., The Journal of Clinical Investigation
Lectures
- Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.2019 ASCO Annual Meeting - 6/1/2019
- SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung c...2019 ASCO Annual Meeting - 6/1/2019
- Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Join now to see all
Authored Content
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Press Mentions
Illumina Posts 78% Revenue Growth as Cancer, DNA Testing Ramp Back UpAugust 6th, 2021- Famed Chef Ming Tsai, Whose Spouse Polly Is A Lung Most Cancers Survivor, Introduces A New Tasty Vegan Dish with A Artful Title; How Diet Impacts Well BeingAugust 1st, 2021
- The Next Cancer BreakthroughsMarch 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
